TABLE 2.
Variables of study in patients under EPS in the first peak of COVID‐19 pandemic
| Variables | COVID‐19 pandemic period | Control period | Variation % | P‐value | |
|---|---|---|---|---|---|
| Total number of EPS | 11 | 55 | −80 | ||
| Gender (male/female) | 5/6 | 23/32 | ‐ | 0.53 | |
| Age (mean ±SD) (years) | 61.45 ± 15.46 | 49.72 ± 15.49 | ‐ | 0.02 | |
| Indication of EPS | PSVT (AVNRT, AVRT) | 7 (63.6%) | 21 (38.1%) | −67 |
0.59 |
| Atrial tachyarrhythmia (AT, AFL, AF) | 1 (9.1%) | 9 (16.3%) | −89 | ||
| Bradyarrhythmia (SAN and AVN diseases) | 1 (9.1%) | 6 (10.9%) | −84 | ||
| PVC/VT | 0 | 6 (10.9%) | −100 | ||
| Others | 2 (18.2%) | 13 (23.6%) | −85 | ||
AT, atrial tachycardia; AF, atrial fibrillation; AFL, atrial flutter; AVN, atrioventricular node; AVNRT, atrioventricular nodal re‐entry tachycardia; AVRT, atrioventricular re‐entry tachycardia; CHB, complete heart block; EPS, electrophysiology study; PSVT, paroxysmal supraventricular tachyarrhythmia; PVC, premature ventricular contraction; SAN, sinoatrial node; VT, ventricular tachycardia.